Kaitlyn D’Onofrio

DocwireNews

High costs of biologics and their use for often long-term care poses a burden to healthcare systems, which could be alleviated by the adoption of biosimilars. Since cancer severely impacts older patients, it is important to evaluate the connection between biosimilars and value-based oncology care models.&nbsp;The use of biologics has increased due to the increase in cancer diagnoses, earlier treatment practices, and improved patient outcomes; these variables, along with high manufacturing costs and increasing healthcare costs, have increased cancer spending.&nbsp;U.S. organizations are developing oncology-focused value assessment frameworks. Some aid physicians and patients in making educated treatment decisions, while others may be beneficial in coverage and reimbursement choices. These frameworks only serve as a guide, however, and have not been adopted as part of an official policy.&nbsp;The U.S. Centers for Medicare &amp; Medicaid Services (CMS) has created frameworks intended to improve quality of care for Medicare beneficiaries. One CMS model was designed to move from fee-for-service (FFS) to more value-based care. This payment model focused on high-quantity&mdash;but not necessarily high-quality&mdash;health care. The Medicare Access and Children&rsquo;s Health Insurance Program Reauthorization Act implemented the CMS Quality Payment Program (QPP), which launched in January 2017 and will be completely implemented by January 2019. The QPP has two payment tracks: The first is a Merit-Based Incentive Payment System, which focuses on predetermined care measures based on quality. The second is Advanced Alternative Payment Models (APMs), which incentivize clinicians to provide high-quality care while remaining economically strategic.&nbsp;The Oncology Care Model (OCM) is an Advanced APM that seeks to provide patients with high-quality care at equal to or better than FFS standards. Under OCM, providers must meet certain metrics and practice reforms, which is a benchmark for payment consideration. As of July 2017, 192 practices and 14 commercial payers were participating in OCM.&nbsp;Physician practices participating in OCM take part in a two-part payment system: a per-beneficiary Monthly Enhanced Oncology Services (MEOS) payment and a performance-based incentive payment. The MEOS payment aids in management and coordination of patient care, and the performance-based incentive payment is based on the practice&rsquo;s semi-annual quality measure progress, as well as how efficiently it minimizes Medicare expenditures.&nbsp;Under the OCM, biosimilars can help reduce costs and increase accessibility to biologic treatments. In addition to their lower cost, biosimilar presence in the market will likely cause manufacturers to lower the prices of the reference products. According to the RAND Corporation, biosimilars will save the U.S. healthcare system an estimated $13 billion to $66 billion between 2014 and 2024.&nbsp;For these savings to occur, biosimilars must be implemented. A Biosimilars Forum 2015-2016 survey revealed that U.S. specialty physicians&mdash;including oncologists&mdash;still lack a certain degree of knowledge about biosimilars. Knowledge gaps include using&nbsp;biosimilarity, the FDA&rsquo;s approval process for&nbsp;biosimilars, the required evidence for a biosimilar safety and efficacy claims, and the definition of interchangeability.&nbsp;Despite these gaps, healthcare providers are warming up to the idea of biosimilars, according to a different survey. When deciding whether to prescribe biosimilars overall, U.S. physicians put the greatest value on efficacy (89%), safety (81%), and patient costs (72%). As more biosimilars hit the market and physicians gain more knowledge, utilization of biosimilars will likely increase. For this to happen, and for potential savings to occur, healthcare providers must be educated on biosimilars. As biosimilars gain traction, value-based incentive programs will benefit providers, payers, and patients.&nbsp;Source:&nbsp;<a href="https://www.dovepress.com/the-role-of-biosimilars-in-value-based-oncology-care-peer-reviewed-fulltext-article-CMAR">Cancer Management and Research&nbsp;</a>

Jayme Locke, MD, MPH

Joel M. Topf, MD, FACP

The Promise of Xenotransplantation

NKF Spring Clinical Meetings 2025

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Sacituzimab Govitecan Showed Modest Activity for CNS Metastases

Triple-Negative Breast Cancer

Latest News

Cost-efficiency and Efficacy of Biosimilars in Oncology

Oncology

High costs of biologics and their use for often long-term care poses a burden to healthcare systems, which could be alleviated by the adoption of biosimilars. Since cancer ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe